

Arvee Laboratories (India) Limited.

49/3 - B, Shyamal Row Houses, Near Shyamal Cross Roads,
Satellite, Ahmedabad - 380 015, Gujarat, India.

Phone : +91 - 79 - 26749036/37/38, Fax : +91 - 79 - 26742600

e-mail : sales@arveelabs.com, Website: www.arveelabs.com

CIN No. :- U24231GJ2012PLC068778.

Formerly Known as Arvee Laboratories (India) Pvt. Ltd.



Date: 30th May, 2018

To,

National Stock Exchange of India Limited

Exchange Plaza, Plot no. C/1, G Block,

Bandra-Kurla Complex, Bandra (E)

Mumbai - 400 051

Equity Scrip Name: ARVEE

Dear Sir /Madam,

**Subject: Outcome of the Meeting of Board of Directors of the Company held on
Wednesday, 30th May, 2018.**

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors at its meeting held today has inter alia:

1. Approved the Audited Financial Results of the Company along with the Auditor's Report for the half year and year ended on 31st March, 2018.
2. Approved the Appointment of Jalan Alkesh & Associates, Company Secretaries, Ahmedabad as Secretarial Auditors for the year 2017 - 2018 and thereafter.
3. Approved Statement of Deviation pursuant to Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, please find attached herewith the following:

- a) Statement Showing the Audited Financial Result for the half year and year ended 31st March, 2018.
- b) Auditor's Report on Audited Financial Results.
- c) Declaration regarding unmodified opinion.

The Meeting of Board of Directors commenced at

and concluded at

Kindly take the same on Record.

Thanking You,

FOR, ARVEE LABORATORIES (INDIA) LIMITED

SHALIN SUDHAKARBHAI PATEL
MANAGING DIRECTOR
DIN: 01779902



ARVEE LABORATORIES (INDIA) LIMITED

CIN: L24231GJ2012PLC068778

Registered Office: 49/3-B, Shyamal Row House, Near Sanjay Tower,

100 Ft Ring Road, Satellite, Ahmedabad - 380015

Tel : 91-79-26749036 - 38; Website : www.arveelabs.com; Email ID : shalin.patel@arveelabs.com



Statement of Audited Financial Results for the half year and year ended on 31st March 2018

Sr. No.	Particulars	(Rs. in lakhs except per share data)				
		Half year ended			Year ended	
		31/03/2018 (Audited)	30/09/2017 (Audited)	31/03/2017 (Audited)	31/03/2018 (Audited)	31/03/2017 (Audited)
I	Revenue from Operations	2,650.52	1,964.16	1,718.44	4,614.68	3,442.32
II	Other Income	7.12	15.83	39.55	22.94	51.38
III	Total Revenue (I + II)	2,657.64	1,979.99	1,757.99	4,637.63	3,493.70
IV	Expenses					
	(a) Purchase Stock-in-Trade goods, work in progress and Stock-in-Trade	1,414.88	1,460.72	1,312.95	2,875.60	1,986.45
	(c) Employee benefit expense	251.35	-137.18	186.39	114.18	186.39
	(d) Financial costs	151.30	126.40	131.33	277.70	254.39
	(e) Depreciation and Amortisation Expense	166.99	165.88	267.66	332.87	347.76
	(f) Other Expenses	107.41	108.07	103.44	215.48	206.88
		413.10	217.11	55.62	630.21	425.80
	Total Expenses	2,505.04	1,941.00	2,057.39	4,446.04	3,407.67
V	Profit before exceptional and extraordinary items and tax (III-IV)	152.60	38.99	-299.40	191.59	86.03
VI	Exceptional Items	-	-	-	-	-
VII	Profit before extraordinary items and tax (V-VI)	152.60	38.99	-299.40	191.59	86.03
VIII	Extraordinary Items	-	-	-	-	-
IX	Profit before Tax (VII-VIII)	152.60	38.99	-299.40	191.59	86.03
X	Tax expense:					
	(1) Current tax	15.48	7.43	-	22.90	16.39
	(2) Deferred tax	59.77	-	-	59.77	-85.54
XI	Profit/(Loss) for the period (IX-X)	77.36	31.56	-299.40	108.91	155.18
XII	Paid up Equity Share Capital (Face Value of Rs. 10/- each)	42.14	40.50	40.50	42.14	40.50
XIII	Earning/(Loss) per Share. Face value of Rs. 10/- each (not annualised)	1.84	0.78	-7.39	2.58	3.83
XIV	Earning per equity share:					
	(1) Basic	1.84	0.78	-7.39	2.58	3.83
	(2) Diluted	1.84	0.78	-7.39	2.58	3.83

NOTES:

- The Above Financial Results were reviewed by the Audit Committee and subsequently approved by the Board of Directors at its Meeting held on 30th May, 2018
- Tax expenses includes current tax, deferred tax, and adjustment of taxes for the earlier years.
- The Board of Directors have not recommended dividend on Equity Shares.
- Figures for the last year ended 31st March 2018 are the balancing figures between the Audited figures between the Audited figures of the year ended on 31st March 2018 and half year ended on 30th September, 2017.
- During the half year ended on 31st March, 2018 the Company has raised 896.60 lacs by way of initial Public Offer. The entire amount of Rs. 896.60 lacs has been utilised towards the purpose stated in the prospectus.
- Pursuant to the Press Release issued by the MCA dated 2nd January, 2015 (Press Release No. 11/10/2009 CL-V), the shares of the Company are listed on NSE SME exchange as referred to in Chapter XB of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, are exempt from the applicability of the Indian Accounting Standard.
- The Company is engaged only in one segment i.e. Bulk drugs. Hence segment reporting is not applicable.
- Previous period's / year's figures have been regrouped / rearranged wherever necessary, to confirm to the current half year's/ year's classification

For, ARVEE LABORATORIES (INDIA) LIMITED


SHALIN SUDHAKARBHAI PATEL
MANAGING DIRECTOR

Date: 30th May, 2018

Place: Ahmedabad

ARVEE LABORATORIES (INDIA) LIMITED

CIN: L24231GJ2012PLC068778



Registered Office: 49/3-B, Shyamal Row House, Near Sanjay Tower,
100 Ft Ring Road, Satellite, Ahmedabad - 380015

Tel : 91-79-26749036 - 38; Website : www.arveelabs.com; Email ID : shalin.patel@arveelabs.com

Statement of Audited Financial Results for the half year and year ended on 31st March 2018

Sr. No.	Particulars	(Rs. in lakhs)	
		As at 31/03/2018 (Audited)	As at 31/03/2017 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholder's Funds		
	(a) Share Capital	551.00	405.00
	(b) Reserves and Surplus	868.90	15.39
	(c) Money received against share warrents	-	-
	Sub-total - Shareholder's Funds	1,419.90	420.39
2	Share Application money pending allotment		
3	Non-Current Liabilities		
	(a) Long Term borrowings	787.77	1,656.54
	(b) Deferred tax liabilities (Net)	73.19	13.42
	(c) Other long term liabilities	-	-
	(d) Long term Provisions	-	-
	Sub-total - Non-Current Liabilities	860.95	1,669.96
4	Current Liabilities		
	(a) Short-term borrowings	680.47	723.63
	(b) Trade Payables	1,228.58	584.08
	(c) Short-term provisions	51.84	36.04
	(d) Other current liabilities	169.93	134.37
	Sub-total - Current Liabilities	2,130.83	1,478.11
	TOTAL EQUITY AND LIABILITIES	4,411.68	3,568.46
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets		
	(i) Tangible assets	1,488.10	1,687.85
	(ii) Intangible assets	-	-
	(iii) Capital work in progress	118.19	-
	(b) Non Current Investment	-	-
	(c) Deferred tax Assets (Net)	-	-
	(d) Long term loans and advances	74.07	15.11
	(e) Other non-current assets	-	-
	Sub-total - Non-current Assets	1,680.36	1,702.96
2	Current assets		
	(a) Current Investment		
	(b) Inventories	815.88	622.39
	(c) Trade receivables	1,548.38	821.56
	(d) Cash and cash equivalents	196.55	96.32
	(e) Short term loans and advances	170.51	325.22
	(f) Other Current Assets		
	Sub-total - Current Assets	2,731.32	1,865.50
	TOTAL - ASSETS	4,411.68	3,568.46

For, ARVEE LABORATORIES (INDIA) LIMITED


 SHALIN SUDHAKARBHAI PATEL
 MANAGING DIRECTOR


Date: 30th May, 2018

Place: Ahmedabad

To
The Board of Directors of
ARVEE LABORATORIES (INDIA) LIMITED
Ahmedabad

We have audited the financial results of **ARVEE LABORATORIES (INDIA) LIMITED** ('the Company') for the year ended 31st March 2018, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing, Obligations And Disclosure Requirements) regulations, 2015.


These half yearly and yearly financial results have been prepared in terms of the Companies Act, 2013 and as per the applicable accounting standards, which is the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these half yearly and yearly financial results:

- (a) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (b) give a true and fair view of the net profit and other financial information for the half year ended 31st March 2018 as well as the year to date results for the period from 01st April 2017 to 31st March 2018.

FOR KCJM & Associates
Chartered Accountants
Firm's registration number: 121324W


Partner
Membership number: 126585
Ahmedabad
30th May, 2018



Arvee Laboratories (India) Limited.

49/3 - B, Shyamal Row Houses, Near Shyamal Cross Roads,
Satellite, Ahmedabad - 380 015, Gujarat, India.

Phone : +91 - 79 - 26749036/37/38, Fax : +91 - 79 - 26742600

e-mail : sales@arveelabs.com, Website: www.arveelabs.com

CIN No. :- U24231GJ2012PLC068778.

Formerly Known as Arvee Laboratories (India) Pvt. Ltd.



Date: 30th May, 2018

To,

National Stock Exchange of India Limited

Exchange Plaza,

Plot no. C/1, G Block,

Bandra-Kurla Complex, Bandra (E)

Mumbai - 400 051

Equity Scrip Name: ARVEE

Dear Sir /Madam,

Sub: Declaration related to Audit Report of the Company for the half year and year ended on 31st March, 2018

Pursuant to Regulation 33 (3) (d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the SEBI notification No. SEBI/LAD-NRO/GN/2016-2017/001 dated 25.05.2016 and SEBI Circular No. CIR/CFD/CMD/56/2016 dated 27.05.2016, we hereby declare that Statutory Auditors of the Company, M/s KCJM & Associates, Chartered Accountant (FRN: 121324W) have issued an Audit Report with unmodified opinion on Audited Financial Results of the Company for the half year and year ended 31st March, 2018.

You are requested to take the above on your record.

FOR AND ON BEHALF OF ARVEE LABORATORIES (INDIA) LIMITED

SHALIN SUDHAKARBHAI PATEL
MANAGING DIRECTOR
DIN: 01779902

